Letter of intent due December 22, application receipt date on January 22, 2010 (just misses the Jan 25 transition to enhanced shorter applications, so these use a 25-p research narrative … “typewritten” paper submission no less).
The goal is to achieve a profound (quantum) impact on the prevention, diagnosis, or treatment of a major disease or national public health problem through the development and implementation of biomedical technologies.
Total costs (i.e., direct plus indirect/F&A costs) for any single year (5-y project period) may not exceed $3M. NIBIB expects most applicants to request $1-3M in total annual costs.
Before you get too excited, only 1-3 awards will be made.
NIBIB made 5 awards in the Phase I competition “on stem cell therapies for diabetes and stroke, nanoparticles to help eliminate brain tumors, development of an implantable device to replace kidney dialysis, and a microchip to capture circulating tumor cells for clinical and research purposes” — but anyone can apply for Phase II funding so long as their research plan “demonstrates the potential for a quantum advance by the end of Phase II via substantial pre-clinical data or a first clinical implementation.”
How much of an advance? NIBIB envisions that the “technology being developed would overcome a major, present-day disease or national public health problem (i.e., leading categories of disease burden, high-mortality/morbidity diseases affecting more than 100,000 individuals annually, technologies that revolutionize over 200,000 procedures annually), or change the paradigm of prevention, diagnosis, treatment in the practice of medicine.” In 5 years. I guess $3M a year will do that for you. I can’t wait to read the way cool announcements in NIH Research Matters.
What I want to know is where NIBIB finds reviewers with the vision needed to foresee a paradigm shift and quantum advance in the practice of medicine within the next 5 years … and whether these reviewers are available to take a look at my 401K portfolio.
Lots more detail in the RFA. Happy reading.